Rocuronium

ApprovedCompleted

0 views this week 0 watching⚡ Active

Interest: 43/100

Hype Score

Development Stage

✓

Pre-clinical

✓

Phase 1

✓

Phase 2

✓

Phase 3

Approved

Indication / Disease

Morbid Obesity

Conditions

Morbid Obesity

Trial Timeline

May 1, 2016 → Oct 1, 2017

NCT ID

NCT02703909

About Rocuronium

Rocuronium is a approved stage product being developed by Merck for Morbid Obesity. The current trial status is completed. This product is registered under clinical trial identifier NCT02703909. Target conditions include Morbid Obesity.

What happened to similar drugs?

2 of 4 similar drugs in Morbid Obesity were approved

Approved (2) Terminated (0) Active (2)

✅MicafunginAstellas PharmaApproved

✅Posaconazole Injection [Noxafil] 300mg + Posaconazole Injection [Noxafil] 400mgMerckApproved

🔄Placebo + IBI362Innovent BiologicsPhase 3

🔄Supemtek® + Vaxigriptetra®SanofiPhase 3

Hype Score Breakdown

Clinical

Activity

Company

Novelty

Community

Clinical Trials (6)

NCT ID	Phase	Status	Start	Completion	Indication
NCT02812186	Approved	Completed	Dec 27, 2016	Feb 6, 2019	Cholecystitis
NCT02703909	Approved	Completed	May 1, 2016	Oct 1, 2017	Morbid Obesity
NCT02553629	Approved	Completed	Sep 1, 2015	Apr 1, 2016	Surgical Conditions
NCT02320734	Approved	Completed	Feb 1, 2015	Sep 1, 2016	Neuromuscular Block
NCT02025075	Pre-clinical	Completed	Jan 1, 2014	Oct 1, 2015	Intraoperative Complications
NCT00902070	Pre-clinical	Completed	Nov 1, 2007	Oct 1, 2010	Anesthesia

Competing Products

7 competing products in Morbid Obesity

See all competitors

Product	Company	Stage	Hype Score
Micafungin	Astellas Pharma	Approved	43
Posaconazole Injection [Noxafil] 300mg + Posaconazole Injection [Noxafil] 400mg	Merck	Approved	43
Placebo + IBI362	Innovent Biologics	Phase 3	47
Supemtek® + Vaxigriptetra®	Sanofi	Phase 3	40
Molindone	Supernus Pharmaceuticals	Phase 2	29
SPN-810M	Supernus Pharmaceuticals	Phase 1	23
SPN-810 + Placebo	Supernus Pharmaceuticals	Phase 2	29